share_log

Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target

Benzinga ·  Dec 11, 2024 05:26  · Ratings

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $11 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment